1. Home
  2. ACET vs PDC Comparison

ACET vs PDC Comparison

Compare ACET & PDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$2.48

Market Cap

28.0M

Sector

Health Care

ML Signal

N/A

Logo Perpetuals.com Ltd American Depositary Shares

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$1.20

Market Cap

24.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
PDC
Founded
1947
2018
Country
United States
Japan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
28.0M
24.2M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
ACET
PDC
Price
$2.48
$1.20
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $29.00
N/A
AVG Volume (30 Days)
★ 284.0K
72.2K
Earning Date
11-05-2026
09-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.13
52 Week High
$9.97
$8.40

Technical Indicators

Market Signals
Indicator
ACET
PDC
Relative Strength Index (RSI) 15.77 31.10
Support Level N/A N/A
Resistance Level $9.51 $3.23
Average True Range (ATR) 0.26 0.49
MACD 0.08 -0.09
Stochastic Oscillator 6.57 7.06

Price Performance

Historical Comparison
ACET
PDC

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About PDC Perpetuals.com Ltd American Depositary Shares

Perpetuals.com Ltd is a financial technology company bridging traditional financial markets with blockchain-based infrastructure. The group operates regulated financial market infrastructure at the intersection of traditional finance and digital assets. Its B2B offerings include capital markets technology delivered as SaaS and institutional-grade custody through Crypto Vault. For consumers, it provides compliant retail trading and prediction market platforms. The group's operations across the USA, Europe, and Asia develop software solutions that enable regulated trading venues to operate with 24/7 self-clearing and blockchain-based settlement technology, empowering institutions to compete in the evolving landscape of digital finance.

Share on Social Networks: